Abstract:Recently, gene therapy has been become a promising approach to cure hemophilia A, a most common recessive bleeding disease. The aim of this study was to determine the perspective of lentiviral vector in hemophilia A gene therapy in vitro and in NOD/SCID mice. Lentivirus transfer vector pXZ9/BDDFVIII containing human B-domain-deleted Factor VIII-IRES-eGFP coding sequence and mock control pXZ9 were constructed. Lentivirus was prepared by co-transfecting 3 plasmids into 293FT cells. 293FT, HLF, human bone marrow mesenchymal stem cells and Chang-liver cells were transfected with the prepared virus. Coagulant activity of human FVIII, human FVIII antigen, human FVIII mRNA transcription and genomic integration were assayed by ELISA, one-step method, RT-PCR and PCR after infection. Lentiviral particles were concentrated by ultracentrifugation and NOD/SCID mice were transfected via portal vein injection. Human FVIII antigen in mouse blood plasma was analyzed by ELISA. eGFP expression was observed by fluorescent microscopy and human FVIII transcription in mouse liver was analyzed by RT-PCR at one month after transduction. The results showed that the high titer of recombinant virus was prepared and used to efficiently transduce the target cells in vitro. At 72 h after transfection, high levels of FVIII activity and FVIII antigen were detected. Human FVIII gene transcription could be detected in the liver of NOD/SCID mice received lentiviral particles carrying FVIII gene. Mouse hepatocytes were transfected with recombinant lentivirus efficiently in vivo. Human FVIII level in mouse blood plasma reached to (49 ± 6) mU, (54 ± 8) mU and (23 ± 4) mU at 72 h, one week and one month after transfection respectively. It is concluded that the lentiviral particles carrying BDDhFVIII gene can high efficiently transfect the target cells both in vitro and in vivo, and the transfected target cells can secrete hFVIII efficiently. The sustained expression of human FVIII in NOD/SCID mice is observed after lentivirus transfection via portal vein injection.

The Mesenchymal Stem Cells Derived from Transgenic Mice Carrying Human Coagulation Factor Viii Can Correct Phenotype in Hemophilia A Mice

Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived from F8-Modified Ipscs.

Phenotypic Correction and Stable Expression of Factor VIII in Hemophilia A Mice by Embryonic Stem Cell Therapy.

Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain

CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A

Ectopic Expression of Factor VIII in MSCs and Hepatocytes Derived from Rdna Targeted Hescs

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Adeno-associated Virus-Mediated Expression of Activated Factor V (fva) for Hemophilia Phenotypic Correction

A high efficient FVIII variant corrects bleeding in hemophilia A mouse model

Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice

Ectopic Expression of FVIII in HPCs and MSCs Derived from Hipscs with Site-Specific Integration of ITGA2B Promoter-Driven BDDF8 Gene in Hemophilia A

Bioengineering Hemophilia A-specific Microvascular Grafts for Delivery of Full-Length Factor VIII into the Bloodstream

Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.

Therapeutic approaches for treating hemophilia A using embryonic stem cells

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

Partial correction of murine hemophilia A with neo-antigenic murine factor VIII

Ssodn-Mediated In-Frame Deletion with CRISPR/Cas9 Restores FVIII Function in Hemophilia A-Patient-Derived Ipscs and ECs

Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

Correction of F8 intron 1 inversion in hemophilia A patient-specific iPSCs by CRISPR/Cas9 mediated gene editing

Rescue of the endogenous FVIII expression in hemophilia A mice using CRISPR-Cas9 mRNA LNPs